Lack of action potential-prolonging effect of terfenadine on rabbit myocardial tissue preparations

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 1, 2004, Pages 131-135

  Masumiya, Haruko ^a,b   Saito, Mariko ^a   Ito, Mie ^a   Matsuda, Tomoyuki ^a   Noguchi, Kazuo ^a   Iida Tanaka, Naoko ^a,c   Tanaka, Hikaru ^a   Shigenobu, Koki ^a  

^a TOHO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c OTSUMA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Action potential duration; Human ether a go go related gene; Purkinje fiber; QT prolongation; Terfenadine

Indexed keywords

POTASSIUM CHANNEL HERG; TERFENADINE; ANTIALLERGIC AGENT; COMPLEMENTARY DNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL STRAIN HEK293; CONTROLLED STUDY; GENE EXPRESSION; HEART MUSCLE POTENTIAL; HEART VENTRICLE; HUMAN; HUMAN CELL; MALE; MICROELECTRODE; NONHUMAN; NUCLEOTIDE SEQUENCE; PURKINJE FIBER; QT PROLONGATION; RABBIT; SINUS NODE; TISSUE PREPARATION; TOXICITY TESTING; ACTION POTENTIAL; ANIMAL; DRUG EFFECT; ELECTROCARDIOGRAPHY; GENETICS; HEART; IN VITRO STUDY; MOLECULAR CLONING;

ACTION POTENTIALS; ANIMALS; ANTI-ALLERGIC AGENTS; CLONING, MOLECULAR; DNA, COMPLEMENTARY; ELECTROCARDIOGRAPHY; HEART; HEART VENTRICLES; HUMANS; MALE; MICROELECTRODES; PURKINJE FIBERS; RABBITS; TERFENADINE;

EID: 3442883939     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.131     Document Type: Article

References (38)

1. Kerin N., Somberg J., Am. Heart J., 128, 575-585 (1994).
2. Salata J., Jurkiewicz N., Wallace A., Stupienski R., Guinosso P., Lynch J., Circ. Res., 76, 110-119 (1995).
3. Zehender M., Hohnloser S., Just H., Cardiovasc. Drugs Ther., 5, 515-530 (1991).
4. Ishii Y., Muraki K., Kurihara A., Imaizumi Y., Watanabe M., Eur. J. Pharmacol., 331, 295-302 (1997).
5. Kodama I., Suzuki R., Kamiya K., Iwata H., Toyama J., Br. J. Pharmacol., 107, 502-509 (1992).
6. Bran S., Murray W., Hirsch I., Palmer J., Arch. Intern. Med., 155, 765-768 (1995).
7. Tanaka H., Nishimaru K., Sekine T., Shijuku T., Shigenobu K., Res. Comm. Pharm. Toxicol., 2, 163-174 (1997).
8. Eckardt L., Haverkamp W., Borggrefe M., Breithardt G., Cardiovasc. Res., 39, 178-193 (1998).
9. Dumotier B., Adamantidis M., Puisieux F., Bastide M., Dupuis B., Drug Dev. Res., 47, 63-76 (1999).
10. Lu H. R., Marien R., Saels A., De Clerck F., J. Cardiovasc. Electrophysiol., 12, 93-102 (2001).
11. Abrahamsson C., Duker G., Lundberg C., Carlsson L., Cardiovasc. Res., 27, 861-867 (1993).
12. Adamantidis M., Lacroix D., Caron J., Dupuis B., J. Cardiovasc. Pharmacol., 26, 319-327 (1995).
13. Puisieux F., Adamantidis M., Dumotier B.. Dupuis B., Br. J. Pharmacol., 117, 1377-1379 (1996).
14. Noguchi K., Ito C., Isobe Y., Fukushima K., Tanaka Y., Tanaka H., Shigenobu K., Pharmacology, 62, 73-79 (2001).
15. Tanaka H., Masumiya H., Kato Y., Shigenobu K., Gen. Pharmacol., 27, 337-340 (1996).
16. Masumiya H., Tanaka H., Shigenobu K., Eur. J. Pharmacol., 335, 15-21 (1997).
17. Warmke J., Ganetzky B., Proc. Natl. Acad. Sci. U.S.A., 91, 3438-3442 (1994).
18. Noguchi K., Karasawa Y., Isobe Y., Fukushima K., Tanaka H., Shigenobu K., Res. Comm. Biol. Psychol. Psychiat., 24, 21-33 (1999).
19. Katayama Y., Fujita A., Ohe T., Findlay I., Kurachi Y., J. Pharmacol. Exp. Ther, 294, 339-346 (2000).
20. Davies A. J., Harindra V., McEwan A., Ghose R. R., BMJ, 298, 325 (1989).
21. Monahan B. P., Ferguson C. L., Killeavy E. S., Lloyd B. K., Troy J., Cantilena L. R., Jr., JAMA, 264, 2788-2790 (1990).
22. Honig P. K., Wortham D. C., Zamani K., Conner D. P., Mullin J. C., Cantilena L. R., JAMA, 269, 1513-1518 (1993).
23. Lang D., Wang C., Wegener T., J. Cardiovasc. Pharmacol., 22, 432-442 (1993).
24. Gintant G., Limberis J., McDermott J., Wegner C., Cox B., J. Cardiovasc. Pharmacol., 37, 607-618 (2001).
25. Kato Y., Mori T., Ohmori K., Ichimura M., Jpn. J. Pharmacol., 70, 199-202 (1996).
26. Pinney S. P., Koller B. S., Franz M. R., Woosley R. L., J. Cardiovasc. Phamacol., 25, 30-34 (1995).
27. Nishio M., Habuchi Y., Tanaka H., Morikawa J., Yamamoto T., Kashima K., J. Pharmacol. Exp. Ther., 287, 293-300 (1998).
28. Crumb W. J., J. Pharmacol. Exp. Ther., 292, 261-264 (2000).
29. Weirich J., Antoni H., Basic Res. Cardiol., 93 (Suppl. 1), 125-132 (1998).
30. Ming Z., Nordin C., J. Cardiovasc. Pharmacol., 26, 761-769 (1995).
31. Wettwer E., Scholtysik G., Schaad A., Himmel H., Ravens U., J. Cardiovasc. Pharmacol., 17 480-487 (1991).
32. Gwilt M., Arrowsmith J. E., Blackburn K. J., Bruges R. A., Cross P. E., Dalrymple H. W., Higgins A. J., J. Pharmacol. Exp. Ther., 256, 318-324 (1991).
33. Reden J., EFPIA/ABPI survey on non-clinical in vivo and in vitro ECG data, 1999, pp. 1-37.
34. Verdonck F., Vereecke J., Vleugels A., Eur. J. Pharmacol., 26, 338-347 (1974).
35. Steinberg M., Greenspan K., Cardiovasc. Res., 10, 236-244 (1976).
36. Pressler M., Warner M., Rubart M., Rardon D., Zipes D., J. Cardiovasc. Electrophysiol., 6, 443-454 (1995).
37. Pourrias B., Porsolt R., Lacroix P., Drug Dev. Res., 47, 55-62 (1999).
38. Picard S., Lacroix P., Curr. Opin. Invest. Drugs, 4, 303-308 (2003).